Gil Roth06.21.11
CIT and LAB Research have re-branded following their merger into CiToxLAB. The newly established group provides preclinical and specialty services from four facilities in France, Canada, Denmark and Hungary, with more than 800 employees and a revenue base in excess of $100 million.
“We are confident that this merger will make CiToxLAB an even more attractive partner for our traditional pharmaceutical and biotech clients,” stated Jean-Francois Le Bigot, president of the new group. “We can offer all the benefits of local, smart-sized facilities, backed up by global resources. Our individual facilities can offer flexibility, direct contact to scientists and easy access to management. In addition, the resources of the group allow us to offer a wider range of services, aggressive scheduling and a broader geographic spread in the clients that we can reach and interact with.”
Mr. Le Bigot added that the new scale and turnkey offerings have attracted interest from big pharma partners. He noted, "The group resources allow us to compete strongly on pricing and timing and we will be seeking to further develop our business with big pharma clients in the coming months.”
The CiToxLAB group is composed of:
The group also works with associate companies and partners such as Atlanbio (St-Nazaire, France), Stemina (Madison, WI) and Biomodels (Boston, MA), to offer access to such services as clinical bioanalysis, embryonic stem cell biomarker discovery and customized preclinical efficacy models.
“We are confident that this merger will make CiToxLAB an even more attractive partner for our traditional pharmaceutical and biotech clients,” stated Jean-Francois Le Bigot, president of the new group. “We can offer all the benefits of local, smart-sized facilities, backed up by global resources. Our individual facilities can offer flexibility, direct contact to scientists and easy access to management. In addition, the resources of the group allow us to offer a wider range of services, aggressive scheduling and a broader geographic spread in the clients that we can reach and interact with.”
Mr. Le Bigot added that the new scale and turnkey offerings have attracted interest from big pharma partners. He noted, "The group resources allow us to compete strongly on pricing and timing and we will be seeking to further develop our business with big pharma clients in the coming months.”
The CiToxLAB group is composed of:
- CiToxLAB France, with 320 staff, 20,000-sq.-m. facilities and 40 years of experience, offering general toxicology studies, reproductive toxicology, carcinogenicity studies, transgenic models, DMPK, bioanalysis, safety pharmacology, TCR (Tissue Cross Reactivity), toxicogenomics and the LEADSCREEN program. The facility has special expertise in NHP toxicology, bone metabolism, nasal administration and immunotoxicology.
- CiToxLAB North America, with 200 staff, 16,000-sq.-m. facilities and 13 years of experience, offering general toxicology studies (including in NHP), reproductive toxicology, DMPK, bioanalysis, immunology services and safety pharmacology. The facility has special expertise in radiation safety, efficacy studies, infusion and inhalation administration.
- CiToxLAB Scantox (Denmark), with 155 staff, 9,000-sq.-m. facilities and 34 years of experience, offering general toxicology studies, reproductive toxicology (including in minipigs), carcinogenicity testing, bioanalysis and genetic toxicology.
- CiToxLAB Hungary, with 130 staff, 15,000-sq.-m. facilities and 40 years of experience, offering general toxicology and inhalation toxicology studies, ecotoxicology and environmental fate studies and a broad range of studies for the registration of chemicals under REACH legislation.
The group also works with associate companies and partners such as Atlanbio (St-Nazaire, France), Stemina (Madison, WI) and Biomodels (Boston, MA), to offer access to such services as clinical bioanalysis, embryonic stem cell biomarker discovery and customized preclinical efficacy models.
